Vaccines against asexual stage malaria parasites

Chemical Immunology

Volumn 80, Issue , 2002, Pages 262-286

  Kumar, Sanjai ^a   Epstein, Judith E ^a   Richie, Thomas L ^a  

^a Office of Blood Review and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MALARIA VACCINE; RECOMBINANT VACCINE; RO 462717; RO 462924; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEROZOITE; NONHUMAN; PARASITE TRANSMISSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

EID: 0036098178     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058849     Document Type: Review

References (139)

1. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum
2. Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications
3. Gamma-globulin and acquired immunity to human malaria
4. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood parasites
5. Widespread distribution of insecticide-impregnated curtains reduces child mortality, prevalence and intensity of malaria infection, and malaria transmission in rural Burkina Faso
6. Impact of permethrin impregnated bednets on child mortality in Kassena-Nankana district, Ghana: A randomized controlled trial
7. EBA-175: An erythrocyte-binding ligand of Plasmodium falciparum
8. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes
9. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro
10. An overview of malaria vaccine development efforts
11. Malaria specific memory T cells: Putative roles of different types of memory responses in immunity and disease
12. Human cerebral malaria in Thailand: A clinico-pathological correlation
13. The molecular basis for the cytoadherence of Plasmodium falciparum-infected erythrocytes to endothelium
14. Chondroitin-4-sulphate (proteoglycan), a receptor for Plasmodium falciparum-infected erythrocytes adherence on brain microvascular endothelial cells
15. The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1
16. Identification of a region on PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: Conserved function with variant sequence
17. Human and murine macrophages produce TNF in response to soluble antigens of Plasmodium falciparum
18. Tumor necrosis factor and disease severity in children with falciparum malaria
19. TNF alpha concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria
20. Glycosylphosphatidylinositols synthesized by asexual erythrocytic stages of the malarial parasite, Plasmodium falciparum, Candidates for plasmodial glycosylphosphatidylinositol membrane anchor precursors and pathogenicity factors
21. Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway
22. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: Molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis
23. Immunization against blood-stage rodent malaria using purified parasite antigens
24. Proteolytic processing of Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains
25. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19kDa C terminal fragment of the merozoite surface antigen, PfMSP1
26. A principal target of human immunity to malaria identified by molecular population genetics and immunological analyses
27. Analysis of sequence diversity in the Plasmodium falciparum mcrozoite surface protein-1 (MSP-1)
28. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth
29. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice
30. Immunization against malaria with a recombinant protein
31. Genetic regulation of protective immune responses in congenic strains of mice vaccinated with a subunit malaria vaccine
32. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP119) of Plasmodium yoelii expressed in Saccharomyces cerevisiae
33. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii
34. Humoral immune response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood stage infection in rodent malaria
35. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria
36. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys
37. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein-1 protects Aotus monkeys against malaria
38. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial
39. Identification of two integral membrane proteins of Plasmodium falciparum
40. 46-53 Kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites
41. Allelic variants of the Plasmodium falciparum merozoite surface antigen 2 (MSA-2) in a geographically restricted area of Irian Jaya
42. A Plasmodium falciparum MSA-2 gene apparently generated by intragenic recombination between the two allelic families
43. Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum
44. Characterization of an inhibitory monoclonal antibody defined epitope on a malaria vaccine candidiate antigen
45. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea
46. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): Increasing prevalence with age and association with clinical immunity to malaria
47. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2
48. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain
49. Characterization of the new merozoite surface protein 4/5 of Plasmodium berghei and P. yoelii
50. Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum
51. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge
52. Biosynthesis of a putative protective Plasmodium knowlesi merozoite antigen
53. Plasmodium falciparum-2 antigens of similar size are located in different compartments of the rhoptry
54. Differential localization of full length and processed forms of PF83/AMA-I an apical membrane antigen of Plasmodium falciparum merozoites
55. Integral membrane protein located in the apical complex of Plasmodium falciparum
56. Analysis of variation in Pf83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum
57. Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum
58. Intra-generic conservation and limited inter-strain variation in a protective minor surface antigen of Plasmodium knowlesi merozoites
59. Structure of the apical membrane antigen-(AMA-l) of Plasmodium chabaudi
60. Apical membrane antigen of Plasmodium fragile
61. Sequence analysis of the apical membrane antigen I (AMA-I) of Plasmodium vivax
62. Sequence analysis of the apical membrane antigen-I genes (ama-I) of Plasmodium yoelii yoelii and Plasmodium berghei
63. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi
64. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66kD merozoite antigen
65. Protective immunity induced in sqirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile
66. CD4+ T Cells acting indepedently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization
67. Specificity of the protective antibody response to apical membrane antigen 1
68. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites
69. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum
70. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion
71. The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites
72. Cloning of Plasmodium vivax Duffy receptor
73. A family of erythrocyte binding proteins of malaria parasites
74. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion
75. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 Region II DNA prime-protein boost immunization regimen
76. Amino acid sequence of the serine-repeat antigen (SERA) of Plasmodium falciparum determined from cloned cDNA
77. Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum
78. Malarial proteases
79. Inhibition of P. falciparum growth in human erythrocytes by monoclonal antibodies
80. Immunity to asexual erythrocytic stages of Plasmodium falciparum: Role of defined antigens in the humoral response
81. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum
82. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: Adjuvant effects on induction of protective immunity
83. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: Further studies using SERA I and MF75.2 adjuvant
84. Complement-mediated killing of Plasmodium falciparum erythrocytic schizont with antibodies to the recombinant serine repeat antigen (SERA)
85. Immune responses induced by gene gun intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum
86. Immune sera recognize on erythrocytes a Plasmodium falciparum antigen composed of repeated amino acid sequences
87. Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum
88. Pf155/RESA antigen localized in dense granules of Plasmodium falciparum merozoites
89. Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion
90. Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components
91. Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf155, react with the native protein and inhibit merozoite invasion
92. Monoclonal antibodies to a synthetic peptide corresponding to a repeated sequence in the Plasmodium falciparum antigen Pf155
93. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum
94. Immunization of owl monkeys with the ring-infected crythrocyte surface of Plasmodium falciparum
95. Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA
96. Genetic and structural relationship between components of a protective rhoptry antigen complex from Plasmodium falciparum
97. Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum
98. The 42-kilodalton rhoptry-associated protein of Plasmodium falciparum
99. Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum
100. A rhoptry antigen of Plasmodium falciparum contains conserved and variable epitopes recognized by inhibitory monoclonal antibodies
101. A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys
102. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys
103. Cloning the Plasmodium falciparum gene encoding PfEMPI, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes
104. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes
105. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum infected erythrocytes
106. Frequent epitopic recombination of virulence factor genes in telomeric chromosome cluster of Plasmodium falciparum
107. Classification of adhesive domains in the Plasmodium falciparum erythrocyte membrane protein 1 family
108. Plasmodium falciparum-infected erythrocytes: Agglutination by diverse Kenyan plasma is associated with severe disease and young host age
109. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria
110. Induction of protective immunity against experimental infection with malaria using synthetic peptides
111. Vaccination with SPf66, a chemically synthesiscd vaccine, against Plasmodium falciparum malaria in Columbia
112. Randomised trial efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania
113. Efficacy trial of malaria vaccine SPf66 in Gambian infants
114. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia
115. Randomised double-bind placebo-controlled trial of SPf66 malaria vaccine in children in Northwestern Thailand
116. Evaluation of SPf66 malaria vaccine efficacy in Brazil
117. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania
118. Safety, Immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults
119. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1-19) and T helper epitopes of tetanus toxoid
120. Malaria vaccine development: Status report
121. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
122. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
123. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ T cell-, interferon gamma-, and nitric oxide-dependent immunity
124. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
125. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
126. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations
127. Control of a mucosal challenge and prevention of AIDS in by a multiprotein DNA/MVA vaccine
128. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses
129. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice
130. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
131. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
132. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture
133. A DNA vaccine encoding the 42-kD terminus of merozoite surface protein 1 and granulocyte-macrophage colony stimulating factor induces antibody, interferon-γ and cytotoxic T cell responses in rhesus monkeys
134. Research (genomics) is crucial to attacking malaria
135. The malaria genome project: From sequence to functional
136. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum
137. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum
138. Malaria research in the post-genomic era